The Green List has a zero-tolerance for illegal listings or prescription products.

November 1st Highlights

  • Cannabis and Pharmaceuticals - Seniors are turning to cannabis to treat - Seniors are turning to cannabis to treat common symptoms of aging, with nearly 80% of those who reported using cannabis saying they did so for medicinal reasons, according to a study from researchers at the University of California San Diego. Results of the study, “Cannabis: An emerging treatment for common symptoms in older adults,” were published this month in the Journal of the American Geriatric Society. To conduct the research, investigators surveyed 568 seniors at a geriatric clinic. All respondents were at least 65 years old, and 73% of those surveyed were older than 75. The researchers discovered that 15% of seniors had used cannabis in the last three years, among whom half reported using cannabis regularly. Cannabis was used primarily for medical reasons by 78% of those who reported its use. Material sourced from here - link
  • The EU Cannabis Advantage - Europe’s emerging infrastructure will be more equipped to enter GMP and pharmaceutical distribution networks than the U.S., since state-by-state rules didn’t require these higher standards of reporting and consistency to get mass distribution. Canada is already retooling facilities to conform to EU-GMP standards and it is costly and drawn out. The US will face this with federal regulation, and it will be an incredible set-back for existing grows and manufacturers to conform to regulatory needs. Australia is also in a similar position for Europe and eventually Asia.  Material sourced from here - link


Study finds 15% of seniors use cannabis to treat symptoms of aging

How Europe’s emerging cannabis markets could affect the global industry

Adult use cannabis does not pass in New Zealand

Cann Global to launch Canntab products in Australia

Billionaire families back early stage medical cannabis company